Vical, Inc. (NASDAQ:VICL)
| CAPS Rating |
|
|---|---|
| Open | $3.45 |
| Previous Close | $3.50 |
| Daily Range | $3.20 - $3.46 |
| 52-Week Range | $1.70 - $5.30 |
| Market Cap | $231.32M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 2,744,889 |
| Average Daily Volume | 0 |
VICL
VS S&P 500 (SPY)
How do you think VICL will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
VICL Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
VICL News and Commentary
- Charting Vical's Latest Earnings Release – The Motley Fool
- 6 Key Drivers for Biotechnology's 2012 Outlook – Minyanville
- Biopharmaceutical Co Vical Prices 13.3M Share Offering At 12% Discount – SmartMoney
- Ending HIV/AIDS: Hedge Funds Believe in These 5 Companies – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Whoa! My Stock Just Crushed the Market! – The Motley Fool
- Chimpcontest update: Ah, the irony! – Blog at The Motley Fool
- Is Dendreon the Perfect Stock? – The Motley Fool
- Vical's CEO Discusses Q2 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
- Vical Transplants Some Firepower – The Motley Fool
- One Biotech Stock to Avoid – The Motley Fool
- What the Avastin Vote Means – Minyanville
- Exelixis, YM Biosciences Lead Losers at Cancer Meeting – Minyanville
- Roche Bests Bristol-Myers with Melanoma Study – Minyanville
- Bristol, Roche Pact Puts Spotlight on Skin Cancer – Minyanville
- 5 Biotechs With Upcoming Clinical Trial Results – The Motley Fool
- 5 Biotech ASCO Abstracts to Watch – The Motley Fool
- Vical, Exelixis Surge as Cancer Meeting Nears – Minyanville
- Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript – SeekingAlpha
- Vical's CEO Discusses Q1 2011 Results - Earnings Call Transcript – SeekingAlpha Transcripts
RSS Headlines
Fool UK
